Our scientists use state of the art technologies to investigate advanced molecular pathways associated with healthcare’s greatest challenges.
Pherros Biosciences progresses all promising medicinal candidates through all phases of pre-clinical and clinical research phases associated with new drug applications. Our researchers design clinical trials to answer specific research questions related to our medical product candidates. Our specific study plans and protocols run through early, small-scale, Phase 1 studies to late-stage, large scale, Phase 3 studies.
We initiate our studies at the molecular level with the aim to design therapeutics that are tailored to the genetic makeup and physical characteristics of specific disease cohorts. Our candidates are evolved through application of scientific method and evaluation in order to ensure the greatest opportunity for broad application and success of our new therapeutics.
Researchers at Pherros Biosciences consistently seek an unmatched level of excellence. Our scientific investigations are groundbreaking and in search of industry-evolving innovations. We use cutting edge technology in the biochemistry and molecular biology fields to maximize the productivity and impact of all of our research on the medical sciences. This allows us to explore diverse scientific topics and to advance them to useful tools for the health care community. Our research focuses on the structural and biochemical activity of gene products and expression, metabolic pathways, molecular mechanisms of metabolism and disease, advances in biotechnology as well as computational biology.
We initiate our studies at the molecular level with the aim to design therapeutics that are tailored to the genetic makeup and physical characteristics of specific disease cohorts. Our candidates are evolved through application of scientific methodology and evaluation in order to ensure the greatest opportunity for broad application and success of our new therapeutics.
Genetic engineering and molecular biology have dawned a new era in the production of a new class of pharmaceuticals – biologics – which are essentially large molecules that are much more complex than the small molecule medicines to which we have grown accustomed.
At Pherros Biosciences, we have embraced, in a responsible manner, the advent of genetic engineering that is intended to lead to novel biologic therapeutics to some of the worst diseases known to mankind.
From cellular signaling, to immunology to virology, we study metabolic pathways and their key players in search of tomorrow’s greatest therapies.